Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA CAR-T for Refractory Sjögren's Syndrome
NCT05085431Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD19/BCMA CAR T-cells in Sjögren's syndrome, sponsored by Zhejiang University. Primary endpoint: Dose-limiting toxicity at 28 days. Status: unknown.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT05085431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085431.